Skip to main navigation News & Publications Careers Contact Us ABOUT NABRIVA PIPELINE & RESEARCH FOR INVESTORS SHAREHOLDER INFORMATION Home / For Investors / Shareholder Information EVENTS & PRESENTATIONS PRESS RELEASES FINANCIAL PERFORMANCE SHARE PERFORMANCE SHAREHOLDER INFORMATION CORPORATE GOVERNANCE EMAIL ALERTS Shareholder Information Stock Basis Issuers of corporate securities are required to complete Internal Revenue Service Form 8937 to report organizational actions, including nontaxable distributions, that affect the basis of the securities involved in the organizational action. The tax information contained herein is provided for informational purposes only and should not be construed as legal or tax advice. Please consult with a qualified tax advisor for questions regarding your specific tax treatment. June 2017 Redomicile IRS Form 8937 – Report of Organizational Actions Affecting Basis of Securities Please refer to this form for information regarding the organizational action whereby Nabriva Therapeutics plc (“Nabriva Ireland”) completed a tender offer to exchange the American depositary shares (“ADS”) and common shares of Nabriva Therapeutics GmbH (“Nabriva GmbH”) for ordinary shares of Nabriva Ireland. July 2018 Acquisition of Zavante Therapeutics, Inc. Form 8937 – Report of Organizational Actions Affecting Basis of Securities Please refer to this form for information regarding the acquisition of Zavante Therapeutics, Inc. by Nabriva Therapeutics plc. Annual General Meeting Documents 2018 Nabriva Convocation Notice for AGM 2018 2017 Nabriva Convocation Notice for AGM 2017 Resolution Proposals for the Annual General Meeting on 30 August 2017 Nabriva Therapeutics Supervisory Board Compensation Policy Jahresabschluss, Nabriva Therapeutics AG, Wien Nabriva Einladung - OHV 2017 Beschlussvorschläge für die OHV 2016 Report of the Supervisory Board of Nabriva Therapeutics AG for the financial year 2016 pursuant to § 96 Austrian Stock Corporation Act Privacy Notice Imprint Disclaimer Contact Us Careers Sitemap © Nabriva Therapeutics plc, Ireland Registration No. 599588, 25-28 North Wall Quay, Dublin 1, Ireland

Skip to main navigation News & Publications Careers Contact Us ABOUT NABRIVA PIPELINE & RESEARCH FOR INVESTORS FINANCIAL PERFORMANCE Home / For Investors / Financial Performance EVENTS & PRESENTATIONS PRESS RELEASES FINANCIAL PERFORMANCE SHARE PERFORMANCE SHAREHOLDER INFORMATION CORPORATE GOVERNANCE EMAIL ALERTS Annual Reports Annual Reports Quarterly Reports SEC Filings YEAR ANNUAL REPORT 10-K PROXY 2020 Irish Statutory Annual Report 2020 2020 10-K 2021 Proxy YEAR ANNUAL REPORT 10-K PROXY 2019 2019 Annual Report 2019 10-K 2019 Proxy YEAR ANNUAL REPORT 10-K PROXY 2018 2018 Annual Report 2018 10-K 2018 Proxy Irish Statutory Annual Report 2018 YEAR ANNUAL REPORT 10-K PROXY 2017 Irish Statutory Annual Report 2017 2017 10-K 2017 Proxy YEAR ANNUAL REPORT 10-K PROXY 2016 2016 Annual Report 2016 10-K 2016 Proxy Privacy Notice Imprint Disclaimer Contact Us Careers Sitemap © Nabriva Therapeutics plc, Ireland Registration No. 599588, 25-28 North Wall Quay, Dublin 1, Ireland